Michael Nissen, MD

The Prince Charles Hospital, Chermside, Australia, Australia

Disclosure(s): CSL Seqirus: Education; GSK: Education; Pfizer: Education

Poster(s):

• (P-45) A Phase 3, Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Investigational Adult-Specific Pneumococcal Conjugate Vaccine, in Pneumococcal Vaccine-Naïve Adults 18–64 Years of Age with Increased Risk for Pneumococcal Disease
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT